1. Introduction {#sec1}
===============

It is well-known that Youyou Tu won the 2015 Nobel Prize in Physiology or Medicine for her discoveries concerning a novel therapy for malaria using artemisinin, which is derived from a traditional herbal medicine called qinghaosu. Since then, Chinese materia medica (CMM) has attracted worldwide attention and has extended to the forefront of the global research community \[[@B1]\].

CMM is an essential component of traditional Chinese medicine; it relies on Chinese medicinal formulas consisting of 2 or more types of CMM and has played a pivotal role in health protection and disease control for thousands of years \[[@B2]\]. In other words, CMM have already provided outstanding clinical results, since they have been tested in human experiments with long-term observation periods and in clinical trials \[[@B3]\]. For instance, Guzhi Zengsheng Zhitongwan (GZZSZTW), a Chinese medicinal formulation created by the national medical master professor Bailing Liu, has been used in the Affiliated Hospital of Changchun University of Chinese Medicine for several decades to treat joint diseases such as osteoarthritis. Clinically, this formula is routinely taken in the form of orally administered pills, which are only produced in the hospital\'s internal preparation center to treat patients, and it is not yet available commercially. Although it is effective and widely used in the treatment of joint diseases in our hospital, the precise molecular mechanism underlying its efficacy in treating osteoarthritis remains to be elucidated.

Osteoarthritis (OA) is the most common degenerative joint and cartilage disease and is associated with pain and disability. However, no suitable treatment for OA exists, because of the poor self-healing capacity of damaged cartilage \[[@B4]\]. Chondrocytes are the only cells residing in cartilage that control cartilage structure and function by regulating extracellular matrix turnover and maintaining cartilage homeostasis \[[@B5]\]. Thus, investigating the effect of the Chinese medicinal formulation GZZSZTW on chondrocytes is therefore very important for further dissecting the molecular mechanism behind its successful clinical treatment of osteoarthritis.

In the present study, we prepared aqueous extracts of GZZSZTW. We isolated primary chondrocytes from neonatal mouse rib cartilage and investigated the effects of GZZSZTW on the proliferation of chondrocytes. We further performed RNA-seq to analyze the gene expression pattern of chondrocytes in response to treatment with GZZSZTW. We demonstrated that GZZSZTW significantly promoted chondrocyte viability, maintained chondrocytes in a continuous proliferative state, and suppressed their further differentiation by increasing the expression levels of genes that promote chondrocyte commitment and proliferation and a decrease in the expression levels of genes that inhibit chondrocyte proliferation and promote chondrocyte differentiation.

2. Materials and Methods {#sec2}
========================

2.1. Preparation of the GZZSZTW Aqueous Extract {#sec2.1}
-----------------------------------------------

GZZSZTW was obtained from the Affiliated Hospital of Changchun University of Chinese Medicine (Changchun, China). The formulation of GZZSZTW consisted of 7 types of CMM, namely,*Rehmannia glutinosa*(Gaertn.) DC.,*Spatholobus suberectus*Dunn,*Epimedium brevicornu Maxim*(K.S.Hao)*, Raphanus sativus L.*(Hook. f. & T. Anderson) (baked),*Drynaria fortunei (*Kunze ex Mett.) J.Sm. (baked),*Cynomorium coccineum subsp. songaricum (Rupr.)*(J.Léonard), and*Cibotium barometz (L.)*(J.Sm). The CMM mixture of GZZSZTW was extracted with distilled water by a reflux method and was then filtered through a 0.45-*μ*m Hollow Fiber Cartridge (GE Healthcare, USA). The filtrate was freeze-dried by a Heto PowerDry LL3000 Freeze Dryer (Thermo, USA) and stored at -80°C.

2.2. Isolation of Primary Chondrocytes {#sec2.2}
--------------------------------------

Animal experiments were approved by the Ethical Committee for Animal Research of Changchun University of Chinese Medicine. Primary chondrocytes from the rib cartilage of neonatal mice were isolated as previously described \[[@B6]\]. Briefly, cartilage from the rib cages of neonatal C57BL/6J mice was digested for 45 minutes with 3 mg/ml collagenase D and then overnight with 0.5 mg/ml collagenase D (Sigma, USA). The cells were centrifuged and resuspended in DMEM/F12 medium (Thermo, USA) containing 5% FCS (Thermo, USA) and 1% penicillin/streptomycin (Sigma, USA).

2.3. Cell Proliferation Assay {#sec2.3}
-----------------------------

The Cell Counting Kit-8 (CCK-8) (Sigma, USA) was used to evaluate chondrocyte proliferation according to the manufacturer\'s protocol. Briefly, primary chondrocytes were seeded into 96-well cell culture plates at a density of 5 × 10^4^ cells/ml (100 *μ*l per well) and cultured at 37°C in a 5% CO~2~ incubator (Thermo, USA) for 4 h. The cell culture medium was then discarded, and each well was rinsed thoroughly with fresh culture medium. The chondrocytes were treated with GZZSZTW at different concentrations (0, 0.2, 0. 4, 0.6, 0.8, and 1.0 mg/ml dissolved in culture medium; 100 *μ*l per well) and subsequently cultured for 24 h. Deer antler extract (DAE) was used as a reference drug and added to the cells in the same way as GZZSZTW. Next, 10 *μ*l of CCK-8 reagent was added, and the cells were incubated for 1 h. The absorbance was measured at 450 nm using an Infinite 200 PRO plate reader (Life Sciences, USA). The cell proliferation rate was calculated as the percentage of cell viability after treatment with GZZSZTW and DAE at different concentrations, respectively.

2.4. RNA Purification and Illumina Sequencing {#sec2.4}
---------------------------------------------

Primary chondrocytes were isolated as described above, seeded into 6-well cell culture plates at a density of 1 × 10^5^ cells/well, and incubated for 4 h. Chondrocytes were treated with GZZSZTW for 24 h or left untreated. Then, the cell culture medium was discarded, and each well was rinsed thoroughly with cold PBS buffer. Total RNA was isolated using TRIzol (Invitrogen, USA) in accordance with the manufacturer\'s protocol. RNA integrity was evaluated using the Agilent 2100 Bioanalyzer (Agilent Technologies, USA). Paired-end mRNA libraries were generated using the TruSeq Stranded mRNA kit (Illumina, USA) according to the manufacturer\'s protocol. High-throughput sequencing of the mRNA libraries was performed on an Illumina HiSeq 2500 platform (Illumina, USA).

2.5. RNA-Seq Data Analysis {#sec2.5}
--------------------------

After RNA-seq, clean reads were obtained by trimming the raw reads to remove the low-quality reads and adapter sequences. The data sets were deposited in the NCBI Sequence Read Archive (SRA) database under accession number SRP125978. The clean reads were aligned with the mouse (*Mus musculus*) reference genome using HISAT \[[@B7]\]. The FPKM algorithm was used to measure the gene expression levels \[[@B8]\]. BLAST was used to perform annotations against the nonredundant (NR) and Swiss-Prot protein databases. DEGseq was used to analyze the differentially expressed genes \[[@B9]\]. Genes with a log~2~ fold change ≥ 1 or ≤ -1 and with a p value ≤ 0.001 were considered to be differentially expressed.

2.6. Quantitative Real-Time PCR (qRT-PCR) Verification {#sec2.6}
------------------------------------------------------

The expression levels of differentially expressed genes were validated by qRT-PCR. Briefly, total RNA was isolated using TRIzol (Invitrogen, USA) in accordance with the manufacturer\'s protocol. cDNA was synthesized using the iScript cDNA Synthesis Kit (Bio-Rad, USA) and amplified using SsoAdvanced Universal SYBR® Green Supermix (Bio-Rad, USA) on a CFX Connect Real-Time PCR Detection System (Bio-Rad, USA) under standard amplification conditions. The gene expression levels were normalized to the mouse beta-actin gene (*Actb*) and calculated using the 2^−ΔΔCT^ method \[[@B10]\].

3. Results {#sec3}
==========

3.1. GZZSZTW Promotes Proliferation in Primary Chondrocytes in a Dose-Dependent Manner {#sec3.1}
--------------------------------------------------------------------------------------

The effect of GZZSZTW on chondrocyte proliferation was measured by the CCK-8 assay. Deer antler extract (DAE), which has been shown to promote chondrocyte viability and keep chondrocytes proliferating continuously, while blocking maturation and further differentiation in a dose-dependent manner, was used as a reference drug \[[@B11]\]. As shown in [Figure 1](#fig1){ref-type="fig"}, chondrocyte viability was significantly increased in a dose-dependent manner with GZZSZTW treatment compared with the untreated control group (0 mg/ml). Since treatment with GZZSZTW at the concentrations of 0.8 mg/ml and 1.0 mg/ml had a similar effect on chondrocyte viability, a concentration of 0.8 mg/ml GZZSZTW was selected for use in the following experiments.

3.2. Sequencing, Genome Mapping, and Functional Annotation {#sec3.2}
----------------------------------------------------------

After Illumina sequencing and data processing, 40,958,510 and 40,961,200 clean reads were obtained from primary chondrocytes not treated with GZZSZTW (Blank) and those treated with GZZSZTW, respectively, as shown in [Table 1](#tab1){ref-type="table"}. The quality assessment showed that the Q30 percentages were greater than 94%, and the GC content percentages were approximately 52%. For the Blank and GZZSZTW-treated samples, 36,258,888 and 36,392,470 reads were aligned to the mouse genome, respectively. In total, 15,788 out of 15,908 (Blank) and 15,566 out of 15,676 (GZZSZTW) transcripts were annotated against the nonredundant (NR) NCBI protein database and Swiss-Prot database, respectively.

3.3. Comparative Analysis of Differentially Expressed Genes {#sec3.3}
-----------------------------------------------------------

The differential expression analysis identified 229 genes that were significantly differentially expressed between the GZZSZTW-treated and Blank groups (log~2~ fold change ≥ 1 or ≤ -1 and p ≤0.001), including 139 upregulated genes and 90 downregulated genes (GZZSZTW versus Blank), as shown in [Table 2](#tab2){ref-type="table"}.

3.4. GZZSZTW Increases the Expression Levels of Multiple Genes That Positively Regulate Chondrocyte Proliferation {#sec3.4}
-----------------------------------------------------------------------------------------------------------------

Because GZZSZTW was able to promote proliferation in primary chondrocytes, we first analyzed the differentially expressed genes that positively regulated chondrocyte proliferation. Based on the results from the RNA-seq analysis, we identified 10 differentially expressed genes that directly promoted cell proliferation, including Tnfaip2, Chi3l1, Tnf, Pfkfb3, Sox8, Jag1, Mafb, Pla2g7, Hnrnpa1, and E2f3. The expression levels of these genes were significantly increased in response to GZZSZTW treatment, as shown in [Table 3](#tab3){ref-type="table"}.

3.5. GZZSZTW Treatment Maintains Chondrocyte Proliferation by Decreasing the Expression Levels of Inhibitors of Cell Proliferation {#sec3.5}
----------------------------------------------------------------------------------------------------------------------------------

We then analyzed the differentially expressed genes that participated in the inhibition of cell proliferation. In total, the expression levels of 7 genes were significantly decreased in response to GZZSZTW treatment. These genes are typically downregulated when cells are in a proliferative state and play a crucial role in inhibiting cell proliferation, as shown in [Table 4](#tab4){ref-type="table"}.

3.6. GZZSZTW Treatment Maintains Chondrocyte Proliferation by Promoting Chondrocyte Proliferation and Suppressing Chondrocyte Differentiation {#sec3.6}
---------------------------------------------------------------------------------------------------------------------------------------------

According to the RNA-seq analysis, the expression levels of pancartilaginous early chondrocyte markers including Sox9, Sox5, Sox6, Acan, Col2a1, Col9a1, Col11a1, Hapln1, and Wwp2 were slightly increased in response to GZZSZTW treatment, as shown in [Table 5](#tab5){ref-type="table"}.

Furthermore, the expression levels of proliferating and prehypertrophic chondrocyte markers including Fgfr3, Matn1, Comp, Ptch1, Runx2, and Runx3 were also slightly increased in response to GZZSZTW treatment. However, the expression levels of the major prehypertrophic and hypertrophic chondrocyte markers including Pth1r, Sp7, Ihh, Bmp6, and Ibsp either decreased slightly or exhibited almost no change in response to GZZSZTW treatment, as shown in [Table 6](#tab6){ref-type="table"}.

3.7. Validation of RNA-Seq Data by qRT-PCR {#sec3.7}
------------------------------------------

To validate the accuracy of the RNA-seq results, we selected 8 of the differentially expressed genes (Tnfaip2, Chi3l1, Sox8, Jag1, Rhob, Dusp6, Rad9a, and Filip1l) and verified their expression profiles using qRT-PCR. The specific primers used in this experiment are listed in [Table 7](#tab7){ref-type="table"}.

The relative fold change of each gene was normalized to the internal reference gene*Actb*. The expression levels of the selected differentially expressed genes measured by qRT-PCR were consistent with the results of the RNA-seq analysis, as shown in [Figure 2](#fig2){ref-type="fig"}.

4. Discussion {#sec4}
=============

GZZSZTW, a Chinese medicinal formulation widely used for treating joint diseases, has been used in the Affiliated Hospital of Changchun University of Chinese Medicine for several decades. However, the precise molecular mechanism underlying the ability of GZZSZTW to treat these diseases remains to be elucidated. In the present study, we investigated the effects of GZZSZTW on primary mouse chondrocytes using state-of-the-art RNA-seq technology. According to the results from the CCK-8 assay, GZZSZTW significantly promoted proliferation in primary chondrocytes in a dose-dependent manner. Furthermore, GZZSZTW almost showed the same effect as DAE at the concentrations of 0.8 mg/ml and 1.0 mg/ml. We then performed RNA-seq to further explore the mechanisms responsible for regulating cell proliferation in response to GZZSZTW treatment.

We first analyzed the differentially expressed genes involved in enhancing cell proliferation. Our results indicated that GZZSZTW significantly increased the expression levels of multiple genes involved in promoting cell proliferation, most of which are highly expressed in tumor cells, such as Tnfaip2, Chi3l1, Tnf, Pfkfb3, Sox8, Jag1, Mafb, Pla2g7, Hnrnpa1, and E2f3. Expression of the Tnfaip2 gene is induced in response to Tnf, which plays a pivotal role in tumor formation and growth. Overexpression of Tnfaip2 significantly promotes tumor cell proliferation, and silencing of Tnfaip2 suppresses proliferation \[[@B12]\]. Chi3l1 is highly expressed in various tumors and possesses oncogenic properties. Chi311 promotes cell proliferation in a similar manner to insulin-like growth factor 1 \[[@B13]\]. Pfkfb3 is overexpressed in many cancers, and it promotes cell proliferation through accelerating cell cycle progression and suppressing apoptosis \[[@B14]\]. Sox8 is highly expressed in many tumor cells, and downregulation of Sox8 suppresses tumor cell proliferation \[[@B15]\]. Jag1, a ligand for the Notch family of receptors, is highly expressed in a variety of tumors. Overexpression of Jag1 enhances tumor cell proliferation \[[@B16]\]. Mafb is a member of the Maf family of transcription factors. Overexpression of Mafb enhances tumor cell proliferation, whereas its knockdown inhibits tumor cell proliferation \[[@B17]\]. Pla2g7 is a cancer-selective biomarker; silencing of Pla2g7 is an antiproliferative and proapoptotic therapeutic approach in cancer treatment \[[@B18]\]. Hnrnpa1 is a member of the heterogeneous nuclear ribonucleoprotein family and is highly expressed in growing mammalian cells. Knockdown of Hnrnpa1 inhibits tumor cell proliferation \[[@B19]\]. E2f3, a member of the E2F family of transcription factors, is critical for the transcriptional activation of genes that control proliferation in both normal and tumor cells \[[@B20]\]. Our results indicated that GZZSZTW treatment significantly promoted chondrocyte proliferation by upregulating the expression levels of functional genes involved in the promotion of cell proliferation.

Consistent with the results discussed above, the expression levels of several functional genes involved in the inhibition of cell proliferation were significantly decreased in response to GZZSZTW treatment, most of which act as tumor suppressors, including Rhob, Dusp6, Plk3, Fgf21, Rad9a, Filip1l, and Rasl11b. Rhob is a member of the Ras homolog family. Rhob serves as a tumor suppressor, and loss of Rhob expression has been reported in a variety of tumor cells \[[@B21]\]. Dusp6 is a negative regulator of tumor cell proliferation, and its expression is significantly decreased in many types of invasive tumor cells. Overexpression of Dusp6 suppresses tumor cell proliferation \[[@B22]\]. Plk3 is a member of the Plk family. Plk3 is downregulated in various types of tumor cells and inhibits tumor cell proliferation and tumorigenesis \[[@B23]\]. Fgf21 is an endocrine factor that inhibits chondrocyte proliferation and thus reduces skeletal growth \[[@B24]\]. Rad9a is a cell cycle checkpoint control protein and is required for cell cycle arrest and DNA damage repair in response to DNA damage \[[@B25]\]. Filip1l is downregulated in many types of tumor cells, and its overexpression results in inhibition of cell proliferation and increased apoptosis \[[@B26]\]. Rasl11b is a member of the Ras-like protein family, and its overexpression leads to decreased cell proliferation \[[@B27]\]. Our results indicated that GZZSZTW treatment significantly promoted chondrocyte proliferation by downregulating the expression levels of functional genes involved in the inhibition of cell proliferation.

According to our RNA-seq analysis, the expression levels of the functional genes involved in chondrocyte proliferation and differentiation were also changed slightly in response to GZZSZTW treatment. For instance, the expression levels of pancartilaginous early chondrocyte markers, including Sox9, Sox5, Sox6, Acan, Col2a1, Col9a1, Col11a1, Hapln1, and Wwp2, were slightly increased in response to GZZSZTW treatment. Sox9 is a master transcription factor that plays a major role during cartilage development through regulation of its target genes, including Sox5, Sox6, Acan, Col2a1, Col9a1, Col11a1, Hapln1, and Wwp2 \[[@B28]--[@B30]\]. We further investigated the expression levels of growth plate cartilage markers at different stages of differentiation. The expression levels of markers of proliferating and prehypertrophic chondrocytes, including Fgfr3, Matn1, Comp, Ptch1, Runx2, and Runx3, were slightly increased in response to GZZSZTW treatment. However, the expression levels of the major markers of prehypertrophic and hypertrophic chondrocytes, including Pth1r, Sp7, Ihh, Bmp6, and Ibsp, either decreased slightly or exhibited almost no change in response to GZZSZTW treatment. These results indicated that GZZSZTW treatment facilitated chondrogenesis, maintained chondrocytes in a proliferative state, and prevented their further differentiation into hypertrophic chondrocytes. However, we also observed that the expression level of Col10a1, a specific marker of prehypertrophic and hypertrophic chondrocytes in growth plate cartilage, was slightly increased in response to GZZSZTW treatment. This observation might be explained by the regulatory function of Sox9, which also serves as an upstream regulator of Col10a1 during the progression toward the hypertrophic stage. Sox9 sustains proliferation in columnar chondrocytes and is also required for chondrocyte hypertrophy, a stage that also includes Col10a1 expression \[[@B31]\].

GZZSZTW is designed according to professor Bailing Liu\'s clinical experiences under the guidance of fundamental theories of traditional Chinese medicine. Among the seven types of CMM in GZZSZTW,*Rehmannia glutinosa and Cynomorium coccineum subsp. songaricum (Rupr.)*are important CMM with the ability to nourish the "kidney". In tradition Chinese medicine, kidney is never a definition in anatomic sense but a functional system which plays crucial roles in storing essence and regulating growth, development, and reproduction \[[@B32], [@B33]\].*Epimedium brevicornu Maxim,*a traditional Chinese herbal medicine, has been widely used in China for the treatment of various diseases, such as arthritis and osteoporosis \[[@B34]\]. Icariin, which is considered the major bioactive component of this herbal medicine, has been shown to suppress articular cartilage and bone loss and prevents joint destruction \[[@B35]\]. The traditional Chinese herbal medicine*Drynaria fortunei* is commonly used to treat musculoskeletal traumatic disorders, such as bone fracture and osteoarthritis \[[@B36], [@B37]\]. Propinqualin, which is similar in chemical structure to the natural phytoestrogens naringenin and genistein, has been considered as the putative active ingredient of*Drynaria fortunei* \[[@B38]\]. However, the role of propinqualin in the regulation of chondrocyte is still largely unknown.*Cibotium barometz*is widely used in Chinese medicinal formulations for the clinical treatment of osteoarthritis. Polysaccharides, one of the most important bioactive components extracted from*Cibotium barometz*, have been shown to stimulate chondrocyte proliferation in vitro by promoting G1/S cell cycle transition \[[@B39]\].

*Spatholobus suberectus* Dunn and*Raphanus sativus L.*are two types of medicinal and edible plants in traditional Chinese medicine.*Spatholobus suberectus* Dunn has been widely used as dietary supplements in addition to its traditional prescription for treating anemia, arthralgia, inflammation, and arthritis. It has been shown that gallic acid is the major compound with the anti-inflammatory effects in*Spatholobus suberectus Dunn* \[[@B40]\]. Im and colleagues have shown that*Spatholobus suberectus* Dunn has a potential therapeutic effect for treating osteoarthritis through preventing extracellular matrix destruction in articular cartilage \[[@B41]\].*Raphanus sativus L.* is an edible root vegetable that is commonly used around the world. The seeds of*Raphanus sativus L*have long been used as anti-inflammatory traditional herbal medicine, and it has been shown that sinapic acid is the major active constituent \[[@B42]\]. Taken together, our results indicated that various herbs and their active components in GZZSZTW synergistically promoted chondrocyte viability and proliferation, but inhibited chondrocyte differentiation, extracellular matrix destruction, and inflammation.

5. Conclusions {#sec5}
==============

The present study demonstrated that the Chinese medicinal formulation GZZSZTW, which has been used for several decades to treat joint diseases (e.g., osteoarthritis), significantly promoted chondrocyte viability and proliferation, maintained chondrocytes in a continuous proliferative state, and inhibited further differentiation. These effects were achieved by the synergistic interactions of various herbs and their active components in GZZSZTW, which increased the expression levels of functional genes participating in chondrocyte commitment and proliferation and decreasing the expression levels of genes involved in chondrocyte differentiation. GZZSZTW treatment also decreased the expression levels of genes that inhibit chondrocyte proliferation. Thus, this study has greatly deepened the current knowledge about the molecular effects of GZZSZTW on chondrocytes. This study has also shed new light on possible strategies to further prevent and treat cartilage-related diseases by using traditional Chinese medicinal formulations.
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![Cell viability assay in primary chondrocytes treated with GZZSZTW and DAE. The CCK-8 kit was used to detect chondrocyte proliferation following treatment with GZZSZTW and DAE at increasing concentrations (0, 0.2, 0.4, 0.6, 0.8, and 1.0 mg/ml) for 24 h, respectively. Cell viabilities were normalized and calculated relative to the untreated group (0 mg/ml). Data are presented as the mean and standard deviation for technical triplicates in an experiment representative of several other independent experiments. *∗* (Δ) represents p \<0.01 and *∗∗* (ΔΔ) represents p \<0.001, computed by the t-test for the difference in cell viability in response to GZZSZTW and DAE treatment, respectively.](ECAM2018-7265939.001){#fig1}

![Gene expression levels of differentially expressed genes validated by qRT-PCR. Gene expression levels for individual genes are presented as the fold change between the GZZSZTW-treated group and the untreated control group.](ECAM2018-7265939.002){#fig2}

###### 

Statistics for the sequencing and assembly results.

  Statistics           Blank        GZZSZTW
  -------------------- ------------ ------------
  Clean reads          40,958,510   40,961,200
  Q30 percentage       94.38        94.42
  GC percentage        52.31        52.49
  Total mapped reads   36,258,888   36,392,470
  Total transcripts    15,908       15,676
  Known transcripts    15,788       15,566

###### 

Statistical analysis of differentially expressed genes (GZZSZTW versus Blank).

  Statistics                       Number
  -------------------------------- --------
  Differentially expressed mRNAs   229
  Upregulated mRNAs                139
  Downregulated mRNAs              90

###### 

Differentially expressed genes that positively regulate chondrocyte proliferation.

  ---------------------------------------------------------------------------------------------------------------------------------------
  Gene name                                                         Blank\   GZZSZTW\   log~2~ fold change (GZZSZTW /Blank)   p value
                                                                    (FPKM)   (FPKM)                                           
  ----------------------------------------------------------------- -------- ---------- ------------------------------------- -----------
  Tumor necrosis factor alpha-induced protein 2 (Tnfaip2)           37.69    129.86     1.78                                  0

  Chitinase-3-like protein 1 (Chi3l1)                               40.76    122.14     1.58                                  1.55E-121

  Tumor necrosis factor (Tnf)                                       9.18     24.24      1.40                                  7.31E-21

  6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (Pfkfb3)   9.68     22.87      1.24                                  1.76E-51

  Transcription factor SOX-8 (Sox8)                                 2.99     15.93      2.41                                  1.25E-50

  Protein jagged-1 (Jag1)                                           6.29     13.38      1.09                                  3.80E-27

  Transcription factor MafB (Mafb)                                  5.08     10.76      1.08                                  6.05E-14

  Platelet-activating factor acetylhydrolase (Pla2g7)               4.33     9.88       1.19                                  1.02E-08

  Heterogeneous nuclear ribonucleoprotein A1 (Hnrnpa1)              0.01     6.60       9.37                                  1.87E-21

  Transcription factor E2F3 (E2f3)                                  2.47     5.44       1.14                                  2.88E-11
  ---------------------------------------------------------------------------------------------------------------------------------------

###### 

Differentially expressed genes that negatively regulate chondrocyte proliferation.

  --------------------------------------------------------------------------------------------------------------------------
  Gene name                                             Blank\   GZZSZTW\   log~2~ fold change (GZZSZTW /Blank)   p value
                                                        (FPKM)   (FPKM)                                           
  ----------------------------------------------------- -------- ---------- ------------------------------------- ----------
  Rho-related GTP-binding protein RhoB (Rhob)           118.64   53.33      -1.15                                 1.51E-97

  Dual specificity protein phosphatase 6 (Dusp6)        18.05    7.41       -1.28                                 1.37E-23

  Serine/threonine-protein kinase PLK3 (Plk3)           16.41    6.27       -1.39                                 3.09E-19

  Fibroblast growth factor 21 (Fgf21)                   14.80    7.37       -1.01                                 7.27E-05

  Cell cycle checkpoint control protein RAD9A (Rad9a)   13.54    6.37       -1.09                                 1.81E-10

  Filamin A-interacting protein 1-like (Filip1l)        9.78     4.84       -1.01                                 4.77E-11

  Ras-like protein family member 11B (Rasl11b)          8.48     3.96       -1.10                                 1.45E-06
  --------------------------------------------------------------------------------------------------------------------------

###### 

Gene expression levels of pancartilaginous early chondrocyte markers.

  -----------------------------------------------------------------------------------------------------------------------------
  Gene name                                             Blank\     GZZSZTW\   log~2~ fold change (GZZSZTW /Blank)   p value
                                                        (FPKM)     (FPKM)                                           
  ----------------------------------------------------- ---------- ---------- ------------------------------------- -----------
  Transcription factor SOX-9 (Sox9)                     22.35      28.25      0.34                                  1.39E-06

  Transcription factor SOX-5 (Sox5)                     2.53       5.17       1.03                                  7.95E-14

  Transcription factor SOX-6 (Sox6)                     11.16      13.09      0.23                                  1.24E-10

  Aggrecan core protein (Acan)                          439.94     554.62     0.33                                  7.55E-177

  Collagen alpha-1(II) chain (Col2a1)                   16294.32   16870.22   0.05                                  3.43E-96

  Collagen alpha-1(IX) chain(Col9a1)                    1024.49    1188.74    0.21                                  4.10E-92

  Collagen alpha-1(XI) chain (Col11a1)                  838.24     1020.09    0.28                                  1.47E-232

  Hyaluronan and proteoglycan link protein 1 (Hapln1)   117.28     132.39     0.17                                  5.60E-10

  NEDD4-like E3 ubiquitin-protein ligase WWP2 (Wwp2)    140.53     166.42     0.24                                  2.99E-14
  -----------------------------------------------------------------------------------------------------------------------------

###### 

Gene expression levels of growth plate chondrocyte markers.

  -----------------------------------------------------------------------------------------------------------------------------------------------
  Gene name                                                                  Blank\   GZZSZTW\   log~2~ fold change (GZZSZTW /Blank)   p value
                                                                             (FPKM)   (FPKM)                                           
  -------------------------------------------------------------------------- -------- ---------- ------------------------------------- ----------
  Fibroblast growth factor receptor 3 (Fgfr3)                                57.13    97.35      0.77                                  2.34E-80

  Cartilage matrix protein (Matn1)                                           102.96   124.45     0.27                                  1.06E-08

  Cartilage oligomeric matrix protein (Comp)                                 712.93   775.11     0.12                                  1.77E-13

  Protein patched homolog 1 (Ptch1)                                          3.92     5.44       0.47                                  2.92E-03

  Runt-related transcription factor 2 (Runx2)                                7.43     10.01      0.43                                  3.02E-05

  Runt-related transcription factor 3 (Runx3)                                4.68     6.26       0.42                                  7.23E-03

  Parathyroid hormone/parathyroid hormone-related peptide receptor (Pth1r)   55.23    54.53      -0.02                                 8.96E-01

  Transcription factor Sp7 (Sp7)                                             3.76     4.04       0.10                                  4.23E-01

  Indian hedgehog protein (Ihh)                                              0.57     0.51       -0.16                                 4.99E-01

  Collagen alpha-1(X) (Col10a1)                                              92.05    122.37     0.41                                  1.71E-25

  Bone morphogenetic protein 6 (Bmp6)                                        4.38     5.37       0.29                                  1.19E-01

  Bone sialoprotein 2 (Ibsp)                                                 78.3     72.73      -0.11                                 1.04E-01
  -----------------------------------------------------------------------------------------------------------------------------------------------

###### 

Primer sequences used in qRT-PCR validation.

  Gene             Primer                   Sequence
  ---------------- ------------------------ ------------------------
  Tnfaip2          Forward primer           AGGAGGAGTCTGCGAAGAAGA
  Reverse primer   GGCAGTGGACCATCTAACTCG    
  Chi3l1           Forward primer           GTACAAGCTGGTCTGCTACTTC
  Reverse primer   ATGTGCTAAGCATGTTGTCGC    
  Sox8             Forward primer           CGAGGGGATACTGCTGAGG
  Reverse primer   AGCTCTGCGTTATGGAGATGC    
  Jag1             Forward primer           CCTCGGGTCAGTTTGAGCTG
  Reverse primer   CCTTGAGGCACACTTTGAAGTA   
  Rhob             Forward primer           GTGCCTGCTGATCGTGTTCA
  Reverse primer   CCGAGAAGCACATAAGGATGAC   
  Dusp6            Forward primer           ATAGATACGCTCAGACCCGTG
  Reverse primer   ATCAGCAGAAGCCGTTCGTT     
  Rad9a            Forward primer           GGCTGTCCATTCGCTATCCC
  Reverse primer   GTGGGGCAAAAAGGAAGCAG     
  Filip1l          Forward primer           AGCACTCAGTCGGCAAATTGA
  Reverse primer   AGCCTCTTATTGAGGTCTCTGC   
  Actb             Forward primer           ACCTTCTACAATGAGCTGCG
  Reverse primer   CTGGATGGCTACGTACATGG     
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